<DOC>
	<DOCNO>NCT02100930</DOCNO>
	<brief_summary>The purpose study able supply experimental combination drug call 3F8 GM-CSF ( also call sargramostim ) patient high-risk neuroblastoma may benefit treatment .</brief_summary>
	<brief_title>Anti-GD2 3F8 Monoclonal Antibody GM-CSF High-Risk Neuroblastoma</brief_title>
	<detailed_description>This treatment use 3F8/GM-CSF isotretinoin : Group 1 patient 1st CR/VGPR ; Group 2 patient ≥2nd CR/VGPR ; Group 3 patient primary refractory NB BM . All patient receive 3F8/GM-CSF 24 month . Road Map/Schema Group 1 ( 1st CR/VGPR ) Group 2 ( ≥2nd CR/VGPR ) patient : Cycle 1 3F8 ( iv ) + GM-CSF subcutaneous ( sc ) ( 1 wk ) 2-4-wk interval Cycle 2 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval* - oral isotretinoin x14 day Cycle 3 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval - oral isotretinoin x14 day Cycle 4 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval - oral isotretinoin x14 day , 14 day , 14 day Cycle 5 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval - oral isotretinoin x14 day , 14 day , 14 day ( 6th cycle ) Cycle 6 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval Cycle 7 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) Continue 6-8-wk interval 24 month 1st dose 3F8 . * assessment BM status standard histology Road Map/Schema Group 3 patient ( BM positive ) : The break end cycle 3F8/GM-CSF start next cycle approximately 2-to-4-weeks 4 cycle achievement CR BM ; subsequent break ~6-8 week . Please see roadmap patient achieve CR BM cycle 1 . Cycle 1 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval* - BM negative Cycle 2 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval* - oral isotretinoin x14 day Cycle 3 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval - oral isotretinoin x14 day Cycle 4 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 2-4-wk interval - oral isotretinoin x14 day Cycle 5 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval - oral isotretinoin x14 day Cycle 6 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval - oral isotretinoin x14 day , 14 day , 14 day ( 6th cycle ) Cycle 7 3F8 ( iv ) + GM-CSF ( sc ) ( 1 wk ) 6-8-wk interval Continue 6-8-wk interval 24 month 1st dose 3F8 . * assessment BM response standard histology</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Diagnosis NB define international criteria,62 i.e. , histopathology ( confirm MSKCC Department Pathology ) BM metastases plus high urine catecholamine level . Highrisk NB , define riskrelated treatment guideline International NB Staging System , i.e. , stage 4 ( age ) without ( &gt; 18 month ) MYCNamplification , 63 MYCNamplified NB stage 1.64,65 Patients CR/VGPR primary refractory NB BM i.e. , NB resistant standard therapy , evidence persistence NB BM histology MIBG scan , finding scan show VGPR . Children adult eligible . Signed informed consent indicate awareness scheduling side effect , well test requirement , program . Existing severe major organ dysfunction , i.e. , renal , cardiac , hepatic , neurologic , pulmonary , gastrointestinal toxicity &gt; = grade 3 , except grade 3 hematologic toxicity . Progressive disease ( PD ) History allergy mouse protein . Active lifethreatening infection . Human antimouse antibody ( HAMA ) titer &gt; 1000 Elisa units/ml . Pregnant woman Inability comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Anti-GD2 3F8 Monoclonal Antibody</keyword>
	<keyword>oral isotretinoin</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>13-260</keyword>
</DOC>